China Commercial Credit (CCCR) Announces Compliance With NASDAQ Bid Price Requirement
- Record-setting rally pushes on as S&P ends week up 3 percent
- Trump's Cohn Pick Most Bullish Sign Yet for Banks - Cowen
- Unusual 11 Mid-Day Movers: (IDXG) (INVN) (EBS) Higher; (SCON) (DTEA) (DLTH) Lower (more...)
- 21st Century Fox (FOXA) offers to acquire Sky for GBP10.75/share
- Coca Cola (KO) Announces James Quincey to Succeed Muhtar Kent as CEO; Kent to Continue as Chairman
Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.
China Commercial Credit, Inc. (Nasdaq: CCCR) is pleased to announce that it has regained compliance with Nasdaq's minimum bid price requirement and market value of listed securities requirement.
On July 6, 2016, China Commercial Credit, Inc. (the "Company") received a written notification from the NASDAQ Stock Market Listing Qualifications Staff indicating that the Company has regained compliance with the $1.00 minimum closing bid price requirement for continued listing on the NASDAQ Capital Market pursuant to NASDAQ Listing Rule 5550(a)(2) (the "Minimum Bid Price Requirement") as the closing bid price of the Company's common stock has been at $1.00 per share or greater for at least 10 consecutive business days.
On September 12, 2016, the Company received another written notification from the NASDAQ Stock Market Listing Qualifications Staff indicating that the Company has regained compliance with the minimum market value of listed securities requirements for The NASDAQ Capital Market pursuant to Listing Rule 5550(b)(2) (the " Market Value of Listed Securities Requirement") as the market value of Company's listed securities has been $35,000,000 or greater for 10 consecutive business days.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Flowers Foods (FLO) and Flowers Baking Reach Settlement in Class Action Lawsuit
- Tesla, Ferrari, Jaguar-Land Rover among automakers now included in Takata air bag recalls - Reuters
- AstraZeneca (AZN) Says FDA Accepts First BLA for Durvalumab in Bladder Cancer with Priority Review
Create E-mail Alert Related CategoriesCorporate News
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!